Volume 16 Supplement 2
Hypothermia in refractory status epilepticus
- Andrea O Rossetti1
© Rossetti; licensee BioMed Central Ltd. 2012
Published: 7 June 2012
Status epilepticus (SE) is a neurological emergency with potentially important mortality and morbidity. After refractoriness to general anesthetics, several pharmacological and nonpharmacological options have been described more or less anecdotally. In this context, and despite animal data supporting neuroprotective actions of brain hypothermia and showing its efficacy in SE models, hypothermia targeting a core temperature of about 33°C for at least 24 hours together with pharmacological sedation has been scarcely reported in adults and children. It seems that this approach rarely allows a sustained control of SE, as seizures tend to recur in normothermic conditions. Conversely, hypothermia has a high evidence level and is increasingly used in postanoxic encephalopathy, both in newborns and adults. Due to the thin available clinical evidence, prospective studies are needed to define the value of hypothermia in SE.
Refractory status epilepticus and its treatment
SE represents the second most frequent neurological emergency after acute stroke, and bears significant risks of morbidity and mortality . SE persisting despite adequate doses of benzodiazepines and at least one antiepileptic drug (AED) is considered refractory (RSE) [2, 3]; this develops in 23 to 43% of patients with SE. RSE is associated with acute, severe and potentially fatal underlying etiologies, such as encephalitis, large stroke, or rapidly progressive primary brain tumors, and may be accompanied by coma; these factors, together with increasing age, represent the most important outcome predictors .
After securing pulmonary and cardiac functions, intravenous administration of a sequence of three groups of drugs represents the mainstay of management : benzodiazepines (the only clearly evidence-based step); classical antiepileptic drugs (AED, mostly phenytoin, valproate, or levetiracetam); and general anaesthetics for RSE. Among anaesthetics, midazolam, propofol, or barbiturates represents the most popular agents, without any hard evidence favoring one specific compound . Anesthetic treatment may lead to various complications (infections, metabolic disturbances, ileus, neuropathy, myopathy, thromboembolic events) ; it is therefore necessary to balance these risks with the benefit of rapid seizure control. Generalized convulsive RSE should be treated rapidly with general anesthetics, given the danger of systemic and neurological injury with ongoing convulsions; conversely, nonconvulsive SE without marked consciousness impairment can be approached more conservatively, as these forms are probably not associated with the same risk of injury [1, 2, 6].
RSE that proves refractory to a first course of general anesthetics implies a (repeated) careful search of the underlying etiology. This condition may be managed in several ways, which mostly rely on small series or case reports [1, 7]. Briefly, pharmacological options may include further use of anesthetics (the three aforementioned, ketamine, isofluorane), other AED (for example, topiramate, lacosamide), or ketogenic diet. Reported nonpharmacological approaches span from resective surgery, through vagus-nerve, electroconvulsive or transcranial magnetic stimulations, to mild therapeutic hypothermia (TH).
While the benefits of hypothermia on patients with head injury were already described by Hippocrates , TH enjoys an only evidence-based status in the setting of adult and pediatric postanoxic encephalopathy, and reduction of intracranial pressure . Its indication for the treatment of other acute brain disorders, including SE and traumatic brain injury, is essentially anecdotic.
Animal data on hypothermia
Low brain temperature exerts beneficial effects on the cascades involved in acute cerebral injuries; several seminal studies have been recently reviewed [9, 10]. Hypothermia reduces brain metabolism and ATP consumption, and leads to decrease of glutamate release, free radicals, oxidative stress, mitochondrial dysfunction and calcium overload. Conversely, brain-derived neurotrophic factor increases; as a result, apoptosis is inhibited. Furthermore, hypothermia reduces reperfusion injury, permeability of the blood-brain barrier, and inflammatory reactions. Of note, most of these mechanisms are involved in the pathophysiology of SE leading to neuronal injury . Various rodent models of SE support the neuroprotective effects of TH, showing (with concomitant benzodiazepines) a reduction of seizure severity in SE triggered by electrical stimulation of limbic structures , and mitigation of seizures, brain edema, and cognitive deficits in kainate-induced SE . Temperature lowering before pilocarpine injections (a proconvulsant) protects against SE and apopotosis . However, TH has received very little attention in clinical settings.
Experience in patients with refractory status epilepticus
More than two decades ago, three children with generalized SE were successfully treated with TH (30 to 31°C) and thiopental . Four adults with SE triggered by limbic encephalitis (two patients), hepatic encephalopathy (one patient) and of unknown origin (one patient) were treated with TH (31 to 35°C) co-administered with midazolam; SE was controlled in all, but two patients later died . Shivering was managed by neuromuscular blockade; vein thrombosis and pulmonary embolism were the reported side effects. Another adult with cryptogenic SE was treated with TH (34°C) and thiopental, but she developed paralytic ileus requiring emergency intestinal resection; she survived after further treatment of her RSE . Ongoing seizures in an infant with a severe developmental disorder were controlled by TH at 35 to 36°C, together with ketamine; subsequently, hemispherectomy had to be carried out . Finally, an abstract in Japanese describes an improved functional outcome in 12 children treated with TH (34 to 36°C) and general anesthesia for febrile SE, as compared with 16 treated with conventional therapy, in a retrospective assessment . Reported TH durations are variable, between 20 hours and several days. These case studies suggest that hypothermia may contribute to seizure control. However, its efficacy seems to be only transient: seizures tend to recur in normothermia. TH may thus represent an option in severely refractory SE, but rather to gain some time as to definitively control seizures.
Recently, it has been recognized that postanoxic SE, even with early myoclonus, does not imply an invariably dismal outcome. It seems that SE occurring during TH, mostly as a seizure suppression EEG pattern, does reflect an extremely severe brain damage, and patients are extremely unlikely to survive [19, 20]; conversely, SE arising after return of normothermia and in presence of a reactive EEG background, and preservation of brainstem reflexes and early cortical somatosensory evoked potentials, may be successfully treated with the usual therapeutic armamentarium; those cases represent at most 10% of patients with postanoxic SE, and a good functional outcome can be reached . This actually suggests that TH (with moderate midazolam or propofol doses) can be sufficient to transitorily control benign postanoxic SE (corroborating its antiepileptic properties), while it does not prevent a poor outcome in more severe forms.
As there is a lack of clinical evidence, mild TH (32 to 36°C) may represent a therapeutic option for RSE, albeit on a patient by patient basis. Barbiturates should be avoided because of the risk of paralytic ileus (thus favoring midazolam or propofol), and mild hypothermia should be administered for 24 to 48 hours. Repeated controls of cardiovascular indices, coagulation parameters and lactate (metabolic acidosis following severe infections or intestinal necrosis), and clinical surveillance (vein thrombosis) are mandatory. A well-designed, prospective trial appears necessary to assess the exact role of TH in SE.
- Rossetti AO, Lowenstein DH: Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011, 10: 922-930. 10.1016/S1474-4422(11)70187-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Holtkamp M: Treatment strategies for refractory status epilepticus. Curr Opin Crit Care. 2011, 17: 94-100. 10.1097/MCC.0b013e328342fab5.View ArticlePubMedGoogle Scholar
- Novy J, Logroscino G, RossettiAO : Refractory status epilepticus: a prospective observational study. Epilepsia. 2010, 51: 251-256. 10.1111/j.1528-1167.2009.02323.x.View ArticlePubMedGoogle Scholar
- Meierkord H, et al: EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010, 17: 348-355. 10.1111/j.1468-1331.2009.02917.x.View ArticlePubMedGoogle Scholar
- Cereda C, Berger MM, Rossetti AO: Bowel ischemia: a rare complication of thiopental treatment for status epilepticus. Neurocrit Care. 2009, 10: 355-358. 10.1007/s12028-008-9168-6.View ArticlePubMedGoogle Scholar
- Shorvon S: The treatment of status epilepticus. Curr Opin Neurol. 2011, 24: 165-170. 10.1097/WCO.0b013e3283446f31.View ArticlePubMedGoogle Scholar
- Shorvon S, Ferlisi M: The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011, 134 (Pt 10): 2802-2818.View ArticlePubMedGoogle Scholar
- Harris OA, et al: The role of hypothermia in the management of severe brain injury: a meta-analysis. Arch Neurol. 2002, 59: 1077-1083. 10.1001/archneur.59.7.1077.View ArticlePubMedGoogle Scholar
- Polderman KH: Induced hypothermia and fever control for prevention and treatment of neurological injuries. Lancet. 2008, 371: 1955-1969. 10.1016/S0140-6736(08)60837-5.View ArticlePubMedGoogle Scholar
- Holzer M: Targeted temperature management for comatose survivors of cardiac arrest. N Engl J Med. 2010, 363: 1256-1264. 10.1056/NEJMct1002402.View ArticlePubMedGoogle Scholar
- Chen JW, Wasterlain CG: Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006, 5: 246-256. 10.1016/S1474-4422(06)70374-X.View ArticlePubMedGoogle Scholar
- Schmitt FC, et al: Anticonvulsant properties of hypothermia in experimental status epilepticus. Neurobiol Dis. 2006, 23: 689-696. 10.1016/j.nbd.2006.05.008.View ArticlePubMedGoogle Scholar
- Wang Y, Liu PP, Li LY, Zhang HM, Li T: Hypothermia reduces brain edema, spontaneous recurrent seizure attack, and learning memory deficits in the kainic acid treated rats. CNS Neurosci Ther. 2011, 17: 271-280. 10.1111/j.1755-5949.2010.00168.x.View ArticlePubMedGoogle Scholar
- Yu L, Zhou Y, Chen W, Wang Y: Mild hypothermia pretreatment protects against pilocarpine-induced status epilepticus and neuronalapoptosis in immature rats. Neuropathology. 2011, 31: 144-151. 10.1111/j.1440-1789.2010.01155.x.View ArticlePubMedGoogle Scholar
- Orlowski JP, et al: Hypothermia and barbiturate coma for refractory status epilepticus. Crit Care Med. 1984, 12: 367-372. 10.1097/00003246-198404000-00006.View ArticlePubMedGoogle Scholar
- Corry JJ, et al: Hypothermia for refractory status epilepticus. Neurocrit Care. 2008, 9: 189-197. 10.1007/s12028-008-9092-9.View ArticlePubMedGoogle Scholar
- Elting JW, Naalt J, Fock JM: Mild hypothermia for refractory focal status epilepticus in an infant with hemimegalencephaly. Eur J Paediatr Neurol. 2010, 14: 452-455. 10.1016/j.ejpn.2009.12.001.View ArticlePubMedGoogle Scholar
- Nakagawa T, et al: [Induced hypothermia/normothermia with general anesthesia prevents neurological damage in febrile refractory status epilepticus in children]. No To Hattatsu. 2011, 43: 459-463.PubMedGoogle Scholar
- Rossetti AO, et al: Prognostic value of continuous EEG monitoring during therapeutic hypothermia after cardiac arrest. Crit Care. 2010, 14: R173-10.1186/cc9276.PubMed CentralView ArticlePubMedGoogle Scholar
- Thenayan EA, et al: Electroencephalogram for prognosis after cardiac arrest. J Crit Care. 2010, 25: 300-304. 10.1016/j.jcrc.2009.06.049.View ArticlePubMedGoogle Scholar
- Rossetti AO, et al: Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia. Neurology. 2009, 72: 744-749. 10.1212/01.wnl.0000343006.60851.62.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.